iShares MSCI Japan ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Japan ETF trades at $97.59, while State Street SPDR S&P Biotech ETF trades at $159.4. Which is the better fit depends on your goals.
| EWJ | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $96.97 | $164.28 |
52-Week Low | $77.93 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.79, up 1.81% today, with a bullish technical signal driven by strong moving average alignment. The fund's performance is influenced by Japanese economic policies, including recent U.S.-Japan currency intervention and domestic stimulus efforts. Key resistance sits at $97, with support at $96. Recent news highlights focus on yen strength and its impact on export-heavy Japanese equities.
The outlook for EWJ is cautiously optimistic, supported by bullish technicals and potential economic tailwinds from Japanese fiscal policy. Risks include yen volatility, export sensitivity to currency moves, and broader Asian market turbulence. Investor sentiment is mixed, balancing policy support against inflation and growth concerns.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →